Oragenics Announces $5,000,000in New Financing, and Changesin Its Board of Directors and Management

ALACHUA, Fla.--(Business Wire)--
Regulatory News:

The Florida based biotechnology firm Oragenics (Paris:ALONI), Inc., announces
that it has closed an investment contract with the Koski Family Limited
Partnership to provide new capital for continuing operations. Pursuant to this
contract, the Koski Family Limited Partnership agreed to invest $4,000,000 (four
million dollars) in equity in exchange for 50,000,000 common shares, and
warrants to purchase 1,000,000 additional shares for $.10 each. The equity
investment consists of $1,500,000 in cash at closing and $2,500,000 in the form
of a non-interest bearing promissory note, to be paid in five equal monthly
installments of $500,000 commencing July 31, 2009. In addition, the Koski Family
Limited Partnership has provided Oragenics, Inc., with a loan in the amount of
$1,000,000 (one million dollars) secured by certain assets owned by Oragenics,
Inc.

Pursuant to the terms of this investment, Richard Welch, Derek Hennecke, and
Kevin Sills have resigned from Oragenics board of directors, and have been
replaced by David Hirsch, Robert C. Koski, and Christine L. Koski. Dr, Jeffrey
Hillman remains on the board of directors, and Christine Koski has assumed the
role of Chairperson of the Board. Ms. Koski currently also serves on the board
of directors of Sun Hydraulics Corporation, NASDAQ:SNHY, based in Sarasota,
Florida. David Hirsch has been appointed CEO of Oragenics, going forward.

David Hirsch, Oragenics` CEO stated: "I would like to thank Rick Welch, Derek
Hennecke, and Kevin Sills, for their dedicated service on the board of directors
during a difficult time for the Company. We are excited about the opportunity to
work with Robert Koski and Christine Koski, and look forward to a productive
relationship."

About Oragenics

Oragenics, Inc. is a biopharmaceutical company engaged in developing unique
proprietary technologies, some of which are being commercialized and sold in the
over-the-counter consumer healthcare market. The company also has a number of
products in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases, diagnostics,
and oral health. The company is located in Progress Corporate Park at 13700
Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus
of the University of Florida in Gainesville.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect the
Company`s current views with respect to future events and financial performance.
These forward-looking statements are based on management`s beliefs and
assumptions and information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar expressions that do
not relate solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking statements because
they are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to those
set forth in our most recently filed annual report on Form 10-KSB and quarterly
report on Form 10-Q, and other factors detailed from time to time in filings
with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.

Oragenics, Inc.
Executive Offices
David Hirsch
Chief Executive Officer
Tel.: +1 386 418 4018
dhirsch@oragenics.com

Copyright Business Wire 2009